Zana Technologies GmbH
Zana is a deep tech healthcare company based in Germany, founded in 2018, that leverages voice and AI to improve health outcomes. Their core technology extracts digital voice biomarkers, which are quantifiable characteristics providing valuable health-related information, acting as early indicators of disease progression. Zana's AI-powered SaaS platform analyzes voice recordings to identify patterns associated with health conditions and predict health scores, offering solutions for proactive care, remote monitoring, and disease prevention. They focus on applications in respiratory diseases and cardiology, developing patient companion apps to detect conditions like heart failure and predict lung function decline in asthma and COPD patients. Zana collaborates with pharmaceutical companies to evaluate drug efficacy and digitize clinical trials, with monitoring providers to enhance care quality and reduce costs, and with MedTech companies to integrate voice analysis into devices. The company highlights its platform's reliability, accuracy (80%+ in ongoing trials), accessibility, scalability, non-invasiveness, data protection, and regulatory independence. Zana has achieved significant milestones, including a CE Mark for its health monitoring platform in 2020 and reaching 100 patients in a clinical study for voice biomarkers in heart failure in 2024.
Zana Technologies GmbH
Zana is a deep tech healthcare company based in Germany, founded in 2018, that leverages voice and AI to improve health outcomes. Their core technology extracts digital voice biomarkers, which are quantifiable characteristics providing valuable health-related information, acting as early indicators of disease progression. Zana's AI-powered SaaS platform analyzes voice recordings to identify patterns associated with health conditions and predict health scores, offering solutions for proactive care, remote monitoring, and disease prevention. They focus on applications in respiratory diseases and cardiology, developing patient companion apps to detect conditions like heart failure and predict lung function decline in asthma and COPD patients. Zana collaborates with pharmaceutical companies to evaluate drug efficacy and digitize clinical trials, with monitoring providers to enhance care quality and reduce costs, and with MedTech companies to integrate voice analysis into devices. The company highlights its platform's reliability, accuracy (80%+ in ongoing trials), accessibility, scalability, non-invasiveness, data protection, and regulatory independence. Zana has achieved significant milestones, including a CE Mark for its health monitoring platform in 2020 and reaching 100 patients in a clinical study for voice biomarkers in heart failure in 2024.
TL;DR
Founded: 2018 (Germany)
Core product: SaaS voice-AI platform extracting digital voice biomarkers
Clinical activity: Clinical studies including a 2024 heart-failure study reaching 100 patients
Regulatory milestone: CE Mark for health monitoring platform (2020)
Team size (reported): 12 employees
Company Overview
Problem Domain
Remote patient monitoring, early detection of cardiopulmonary deterioration, and clinical research support.
Founded
2018
Industry
Healthcare / Digital Health / MedTech
Funding Track Record
460000.00
Investor Signal
“Selected as a Gold Company by the EIT Health Investor Network (January 2022); engaged with programs including EXIST and Plug and Play Insurtech”